Johnson & Johnson (J&J) has made a major move to strengthen its US manufacturing operations by signing a $2 billion, 10-year deal with Fujifilm Biotechnologies. This agreement allows J&J to use a large facility in Fujifilm’s new biopharmaceutical plant in Holly Springs, North Carolina. The deal is part of J&J’s ongoing effort to bring more of its production back to the US, which is expected to create about 120 new jobs. This comes as the US government encourages companies to invest more in domestic manufacturing, partly due to rising trade tensions and tariffs. J&J’s CEO, Joaquin Duato, emphasized the company’s strong commitment to US manufacturing, stating that J&J has more production facilities in the US than in any other country. He also highlighted recent US laws, like the One Big Beautiful Bill Act, which provides tax incentives for companies that manufacture drugs in the US. This law, signed in July 2025, includes healthcare reforms and makes it easier for companies to produce and price specialty drugs. The US government has also taken steps to increase the stockpile of key drug ingredients and support new manufacturing sites through programs like the FDA PreCheck. J&J had already announced plans to invest $55 billion over the next four years in US manufacturing, research, and technology. Other major drug companies, like AstraZeneca and Roche, are also making big investments in US production. This trend shows how pharmaceutical companies are adapting to government policies and market pressures by expanding their US operations.